ブックタイトル血管内留置カテーテル由来感染の予防のためのCDCガイドライン 2011｜株式会社メディコン

概要

血管内留置カテーテル由来感染の予防のためのCDCガイドライン 2011｜株式会社メディコン

303. Gristina AG. Biomaterial-centered infection: microbial adhesion versus tissue integration. Science 1987;237:1588?95.304. Timsit JF, Farkas JC, Boyer JM, et al. Central vein catheter-related thrombosis in intensive care patients:incidence, risks factors, and relationship with catheter-related sepsis. Chest 1998; 114:207?13.305. Eastman ME, Khorsand M, Maki DG, et al. Central venous device-related infection and thrombosis inpatients treated with moderate dose continuous-infusion interleukin-2. Cancer 2001; 91:806?14.306. Abdelkefi A, Torjman L, Ladeb S, et al. Randomized trial of prevention of catheter-related bloodstreaminfection by continuous infusion of low-dose unfractionated heparin in patients with hematologic andoncologic disease. J Clin Oncol 2005; 23:7864?70.307. Mermel LA, Stolz SM, Maki DG. Surface antimicrobial activity of heparin-bonded and antisepticimpregnatedvascular catheters. J Infect Dis 1993; 167:920?4.308. Pierce CM, Wade A, Mok Q. Heparin-bonded central venous lines reduce thrombotic and infectivecomplications in critically ill children. Intensive Care Med 2000; 26:967?72.309. Appelgren P, Ransjo U, Bindslev L, Espersen F, Larm O. Surface heparinization of central venous cathetersreduces microbial colonization in vitro and in vivo: results from a prospective, randomized trial. Crit CareMed 1996; 24:1482?9.310. Abdelkefi A, Achour W, Ben Othman T, et al. Use of heparin-coated central venous lines to preventcatheter-related bloodstream infection. J Support Oncol 2007; 5:273?8.311. Carrasco MN, Bueno A, de las Cuevas C, et al. Evaluation of a triple-lumen central venous heparin-coatedcatheter versus a catheter coated with chlorhexidine and silver sulfadiazine in critically ill patients. IntensiveCare Med 2004; 30:633?8.312. Levy JH, Hursting MJ. Heparin-induced thrombocytopenia, a prothrombotic disease. Hematol Oncol ClinNorth Am 2007; 21:65?88.313. Weijmer MC, Debets-Ossenkopp YJ, Van De Vondervoort FJ, ter Wee PM. Superior antimicrobial activity oftrisodium citrate over heparin for catheter locking. Nephrol Dial Transplant 2002; 17:2189?95.314. Boraks P, Seale J, Price J, et al. Prevention of central venous catheter associated thrombosis usingminidose warfarin in patients with haematological malignancies. Br J Haematol 1998; 101:483?6.315. Bern MM, Lokich JJ, Wallach SR, et al. Very low doses of warfarin can prevent thrombosis in centralvenous catheters. A randomized prospective trial. Ann Intern Med 1990; 112:423?8.316. Akl EA, Karmath G, Yosuico VED, Kim SY, Barba M, Sperati F, Cook D, Schu¨nemann H. Anticoagulationfor thrombosis prophylaxis in cancer patients with central venous catheters. Cochrane Database ofSystematic Reviews 2007; Issue 3. Art. No.: CD006468. DOI: 10.1002/ 14651858.CD006468.pub2.317. Akl EA, Muti P, Schunemann HJ. Anticoagulation in patients with cancer: an overview of reviews. Pol ArchMed Wewn 2008; 118:183?93.318. Klerk CP, Smorenburg SM, Buller HR. Thrombosis prophylaxis in patient populations with a central venouscatheter: a systematic review. Arch Intern Med 2003; 163:1913?21.319. Heaton DC, Han DY, Inder A. Minidose (1 mg) warfarin as prophylaxis for central vein catheter thrombosis.Intern Med J 2002; 32:84?8.320. Masci G, Magagnoli M, Zucali PA, et al. Minidose warfarin prophylaxis for catheter-associated thrombosis incancer patients: can it be safely associated with fluorouracil-based chemotherapy? J Clin Oncol 2003;21:736?9.321. Kuter DJ. Thrombotic complications of central venous catheters in cancer patients. Oncologist 2004; 9:207?16.65